vs

Side-by-side financial comparison of FEDERAL SIGNAL CORP (FSS) and Moderna (MRNA). Click either name above to swap in a different company.

Moderna is the larger business by last-quarter revenue ($1.0B vs $597.1M, roughly 1.7× FEDERAL SIGNAL CORP). FEDERAL SIGNAL CORP runs the higher net margin — 10.2% vs -19.7%, a 29.9% gap on every dollar of revenue. On growth, FEDERAL SIGNAL CORP posted the faster year-over-year revenue change (26.5% vs -45.4%). FEDERAL SIGNAL CORP produced more free cash flow last quarter ($89.5M vs $-880.0M). Over the past eight quarters, FEDERAL SIGNAL CORP's revenue compounded faster (18.5% CAGR vs -45.0%).

The Federal Signal Company was an American manufacturer of railway signaling equipment in the early 20th century. It was located in Albany, New York.

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

FSS vs MRNA — Head-to-Head

Bigger by revenue
MRNA
MRNA
1.7× larger
MRNA
$1.0B
$597.1M
FSS
Growing faster (revenue YoY)
FSS
FSS
+71.9% gap
FSS
26.5%
-45.4%
MRNA
Higher net margin
FSS
FSS
29.9% more per $
FSS
10.2%
-19.7%
MRNA
More free cash flow
FSS
FSS
$969.5M more FCF
FSS
$89.5M
$-880.0M
MRNA
Faster 2-yr revenue CAGR
FSS
FSS
Annualised
FSS
18.5%
-45.0%
MRNA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FSS
FSS
MRNA
MRNA
Revenue
$597.1M
$1.0B
Net Profit
$60.8M
$-200.0M
Gross Margin
28.4%
79.6%
Operating Margin
14.0%
-25.6%
Net Margin
10.2%
-19.7%
Revenue YoY
26.5%
-45.4%
Net Profit YoY
21.6%
-1638.5%
EPS (diluted)
$0.99
$-0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSS
FSS
MRNA
MRNA
Q4 25
$597.1M
Q3 25
$555.0M
$1.0B
Q2 25
$564.6M
Q1 25
$463.8M
Q4 24
$472.0M
$966.0M
Q3 24
$474.2M
$1.9B
Q2 24
$490.4M
Q1 24
$424.9M
Net Profit
FSS
FSS
MRNA
MRNA
Q4 25
$60.8M
Q3 25
$68.1M
$-200.0M
Q2 25
$71.4M
Q1 25
$46.3M
Q4 24
$50.0M
$-1.1B
Q3 24
$53.9M
$13.0M
Q2 24
$60.8M
Q1 24
$51.6M
Gross Margin
FSS
FSS
MRNA
MRNA
Q4 25
28.4%
Q3 25
29.1%
79.6%
Q2 25
30.0%
Q1 25
28.2%
Q4 24
28.1%
23.5%
Q3 24
29.6%
72.4%
Q2 24
29.4%
Q1 24
27.3%
Operating Margin
FSS
FSS
MRNA
MRNA
Q4 25
14.0%
Q3 25
16.9%
-25.6%
Q2 25
17.3%
Q1 25
14.2%
Q4 24
14.9%
-129.0%
Q3 24
16.0%
-3.8%
Q2 24
16.5%
Q1 24
12.8%
Net Margin
FSS
FSS
MRNA
MRNA
Q4 25
10.2%
Q3 25
12.3%
-19.7%
Q2 25
12.6%
Q1 25
10.0%
Q4 24
10.6%
-115.9%
Q3 24
11.4%
0.7%
Q2 24
12.4%
Q1 24
12.1%
EPS (diluted)
FSS
FSS
MRNA
MRNA
Q4 25
$0.99
Q3 25
$1.11
$-0.51
Q2 25
$1.16
Q1 25
$0.75
Q4 24
$0.80
$-2.91
Q3 24
$0.87
$0.03
Q2 24
$0.99
Q1 24
$0.84

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSS
FSS
MRNA
MRNA
Cash + ST InvestmentsLiquidity on hand
$63.7M
$1.1B
Total DebtLower is stronger
$564.6M
Stockholders' EquityBook value
$1.4B
$9.3B
Total Assets
$2.4B
$12.1B
Debt / EquityLower = less leverage
0.41×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSS
FSS
MRNA
MRNA
Q4 25
$63.7M
Q3 25
$54.4M
$1.1B
Q2 25
$64.7M
Q1 25
$57.5M
Q4 24
$91.1M
$1.9B
Q3 24
$73.7M
$1.6B
Q2 24
$48.6M
Q1 24
$48.9M
Total Debt
FSS
FSS
MRNA
MRNA
Q4 25
$564.6M
Q3 25
$201.2M
Q2 25
$258.3M
Q1 25
$266.9M
Q4 24
$204.4M
Q3 24
$223.3M
Q2 24
$248.8M
Q1 24
$266.8M
Stockholders' Equity
FSS
FSS
MRNA
MRNA
Q4 25
$1.4B
Q3 25
$1.3B
$9.3B
Q2 25
$1.3B
Q1 25
$1.2B
Q4 24
$1.2B
$10.9B
Q3 24
$1.1B
$11.9B
Q2 24
$1.1B
Q1 24
$1.0B
Total Assets
FSS
FSS
MRNA
MRNA
Q4 25
$2.4B
Q3 25
$1.9B
$12.1B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$1.8B
$14.1B
Q3 24
$1.7B
$15.8B
Q2 24
$1.7B
Q1 24
$1.7B
Debt / Equity
FSS
FSS
MRNA
MRNA
Q4 25
0.41×
Q3 25
0.15×
Q2 25
0.20×
Q1 25
0.22×
Q4 24
0.17×
Q3 24
0.19×
Q2 24
0.23×
Q1 24
0.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSS
FSS
MRNA
MRNA
Operating Cash FlowLast quarter
$97.2M
$-847.0M
Free Cash FlowOCF − Capex
$89.5M
$-880.0M
FCF MarginFCF / Revenue
15.0%
-86.6%
Capex IntensityCapex / Revenue
1.3%
3.2%
Cash ConversionOCF / Net Profit
1.60×
TTM Free Cash FlowTrailing 4 quarters
$227.1M
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSS
FSS
MRNA
MRNA
Q4 25
$97.2M
Q3 25
$61.1M
$-847.0M
Q2 25
$59.7M
Q1 25
$36.7M
Q4 24
$90.6M
$825.0M
Q3 24
$68.8M
$-1.6B
Q2 24
$40.6M
Q1 24
$31.3M
Free Cash Flow
FSS
FSS
MRNA
MRNA
Q4 25
$89.5M
Q3 25
$54.1M
$-880.0M
Q2 25
$52.4M
Q1 25
$31.1M
Q4 24
$82.1M
$303.0M
Q3 24
$60.9M
$-1.7B
Q2 24
$24.8M
Q1 24
$22.9M
FCF Margin
FSS
FSS
MRNA
MRNA
Q4 25
15.0%
Q3 25
9.7%
-86.6%
Q2 25
9.3%
Q1 25
6.7%
Q4 24
17.4%
31.4%
Q3 24
12.8%
-92.2%
Q2 24
5.1%
Q1 24
5.4%
Capex Intensity
FSS
FSS
MRNA
MRNA
Q4 25
1.3%
Q3 25
1.3%
3.2%
Q2 25
1.3%
Q1 25
1.2%
Q4 24
1.8%
54.0%
Q3 24
1.7%
8.1%
Q2 24
3.2%
Q1 24
2.0%
Cash Conversion
FSS
FSS
MRNA
MRNA
Q4 25
1.60×
Q3 25
0.90×
Q2 25
0.84×
Q1 25
0.79×
Q4 24
1.81×
Q3 24
1.28×
-120.46×
Q2 24
0.67×
Q1 24
0.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FSS
FSS

Vehiclesandequipment$403.4M68%
Parts$66.8M11%
Publicsafetyandsecurityequipment$62.2M10%
Rentalincome$19.0M3%
Industrialsignalingequipment$18.2M3%
Other$14.9M2%
Warningsystems$12.6M2%

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

Related Comparisons